市場調查報告書
商品編碼
1126401
質子治療全球市場規模、份額和行業趨勢分析報告:按產品類型、適應症(中樞神經系統癌、前列腺癌、頭頸癌、乳腺癌等)、用戶、地區展望和預測2022-2028Global Proton Therapy Market Size, Share & Industry Trends Analysis Report By Product Type, By Indication (CNS Cancer, Prostate Cancer, Head & Neck Cancer, Breast Cancer and Others), By End User, By Regional Outlook and Forecast, 2022 - 2028 |
預計到 2028 年,全球質子治療市場規模將達到 9.636 億美元,在預測期內以 12.5% 的複合年增長率增長。
多用於惡性腫瘤的生長治療。 X 射線輻射由質子束消散,確保對周圍健康組織的損害較小。放射療法,稱為質子療法,最常用於治療癌症。與傳統放療相比,它的重要優勢在於療效和副作用有限。
質子療法是一種簡單而安全的治療方法,可以讓患者保持快樂並快速恢復正常運動。醫療專業人員可以給予全部或更高的治療劑量以徹底根除原發性腫瘤,而不會嚴重損害周圍的健康組織和器官。
COVID-19 影響分析
COVID-19 大流行正在對醫療器械行業產生全球影響,尤其是粒子治療設備。在 COVID-19 大流行期間,粒子治療程序的實施因地區而異。隨著政府和當局努力確保為 COVID-19 患者提供資源,一些擇期手術將被暫時推遲,預計這將影響質子治療市場。在全球範圍內,癌症負擔預計將增加。這是由於診斷和治療程序的延誤。
市場增長因素
質子療法與粒子療法相比的優勢
近年來,質子療法取得了相當大的技術突破。這些發展使製造商能夠開發出侵入性更小、更有效、使健康組織受到更少輻射且副作用更少的質子治療系統。可以更精確地靶向癌細胞和腫瘤。由於產生的能量較少,接收的輻射較少,因此不太可能影響附近的健康組織和器官。
發展中國家的醫療費用上漲
世界各國政府對醫療保健領域的投資增加和規模是推動市場擴大的因素之一。在新興國家,快速的經濟增長和不斷上漲的醫療保健成本預計將增加獲得優質醫療保健的機會。這被視為質子治療領域的一個有希望的增長信號。在這些國家,癌症發病率的上升增加了對各種放射療法和設備的需求。
市場製約因素
質子治療手術中難以確認腫瘤。
在質子治療手術期間無法將腫瘤與健康的正常組織分開顯示是遇到的最大問題之一。然而,由於腫瘤會定期改變其結構,因此很難將輻射僅針對惡性腫瘤的突出部位而不損害周圍組織。放射科醫生會在腫瘤周圍創造一個安全邊際以減少這種情況。此外,必須限制照射區域以減少對鄰近健康組織的損傷,增加破壞腫瘤細胞所需的治療週期數。
產品類型展望
質子治療市場按產品類型分為加速器、光束傳輸系統、光束傳輸系統、噴嘴和圖像查看器以及患者定位系統。加速器部分在 2021 年佔據了質子治療市場的最大收入份額。癌症發病率上升、相對於進口放射性示蹤劑的成本優勢以及最先進的診斷工具的可用性進一步推動了質子治療市場的增長。質子束療法是一種在加速器中分解氫原子,分離質子和電子,加速分離的質子,並將其轉化為安全能量的治療方法。
適應症
質子治療市場按適應症細分為頭頸癌、中樞神經系統癌、前列腺癌、乳腺癌等。 2021 年,頭頸癌部門在質子治療市場中佔據了很大的收入份額。在質子治療期間,遠離腫瘤的正常組織可以倖免,因為質子粒子不會產生出口劑量。這對這些腫瘤非常有用,因為幾乎所有頭頸部區域的癌症都存在解剖學限制。
最終用戶視角
質子治療市場按最終用戶細分為醫院、質子治療中心等。 2021 年,醫院部門在質子治療市場中的收入份額最高。由於癌症患病率上升、醫院基礎設施改善、高科技設備的使用以及對疾病的自我意識增強,預計這一趨勢將在預測期內持續。
區域展望
按地區分析了北美、歐洲、亞太地區和 LAMEA 的質子治療市場。北美地區將在 2021 年佔據質子治療市場的最大收入份額。在可預見的未來,這種主導地位預計將持續存在。這是由於強大的醫療保健系統、老年患者的增加、醫療保健系統中有利的報銷規定以及提供質子治療的醫療保健設施的增加。
The Global Proton Therapy Market size is expected to reach $963.6 million by 2028, rising at a market growth of 12.5% CAGR during the forecast period.
Proton radiation devices are used in proton therapy, sometimes referred to as proton radiotherapy and proton beam therapy. Utilizing proton treatment, cancer cells are destroyed. In proton therapy, a beam of protons is directed towards the tumors using proton accelerators. Protons are ionized protons that damage cells' DNA and cause cell death by interfering with it.
Equipment for proton therapy is expensive and takes up a lot of space. It includes electro-magnets, accelerators, gantries, nozzles, and patient rooms. High-energy beams are used in proton treatment, also known as proton radiation, to treat malignancies. A precise dose of high-energy radiation is kept inside the target tumor using this procedure.
The majority of the time, it is used in the treatment of malignant growth therapy. X-beam radiation is dissipated by protons, ensuring less damage to the surrounding healthy tissues. Radiation therapy called proton therapy is most frequently used to treat cancer. When compared to conventional radiation therapy, it offers important advantages in terms of effectiveness and limited side effects.
It is a simple, safe procedure that maintains patients' happiness and enables them to quickly resume routine exercises. It enables medical professionals to administer full or greater therapy doses that completely eradicate the primary tumor spot without seriously harming surrounding healthy tissue or organs.
Covid-19 Impact Analysis
The COVID-19 pandemic has affected the medical equipment sector globally, especially particle treatment devices. The administration of particle treatment procedures during the COVID-19 pandemic varies greatly from location to region. The temporary deferral of several elective surgeries is anticipated to affect the market for proton therapy as governments and authorities work to guarantee that resources are available for COVID-19 patients. It is predicted to increase the worldwide cancer burden. The delay in diagnosis and treatment procedures is to blame for this.
Market Growth Factors
Benefits of proton therapy compared to particle therapy
Proton treatment has seen considerable technological breakthroughs in recent years. These developments have aided manufacturers in creating less invasive, more effective, and regulated proton treatment systems that also cause less radiation exposure to healthy tissues and have fewer adverse effects. More precisely targets cancer cells and tumors. A less amount of energy is produced, and there is a smaller exit dose, lowering the possibility of harm to the nearby healthy tissues and organs.
Rising healthcare spending in developing nations
The increasing number and size of investments made in the healthcare sector by governments of various nations is one of the key drivers fuelling the market's expansion. Due to their rapid economic growth and rising healthcare costs, it is projected that the availability of high-quality healthcare would increase in several developing countries. This is regarded as a promising sign of growth for the proton therapy sector. The rising incidence of cancer in these countries has increased the need for various radiation therapies and equipment.
Market Restraining Factors
Tumors are difficult to see during proton treatment operations.
The inability to distinguish tumors from healthy normal tissue and to visualize them during proton treatment procedures is one of the biggest problems encountered. It becomes extremely challenging to only radiate the malignant protrusion without damaging the surrounding tissues, though, because tumors can change their structure regularly. Radiologists place a safety margin around the tumor to reduce this. Additionally, it becomes imperative to restrict the radiation dose range to reduce the harm to the adjacent healthy tissue, which raises the number of treatment cycles required to destroy tumorous cells.
Product Type Outlook
Based on the Product Type, the Proton Therapy Market is segmented into Accelerator, Beam Transport systems, Beam Delivery systems, Nozzle and Image Viewers, and Patient Positioning System. The accelerator segment garnered the largest revenue share in the proton therapy market in 2021. Proton therapy market growth is further aided by the rising incidence of cancer, cost advantages over imported radioactive tracers, and accessibility of cutting-edge diagnostic tools. Starting with a hydrogen atom, the accelerator splits it apart, separates the proton from the electron, and then accelerates the isolated proton to carry as much energy as is safe.
Indication Outlook
On the basis of Indication, the Proton Therapy Market is divided into Head and Neck Cancer, CNS Cancer, Prostate Cancer, Breast Cancer, and Others. The head and neck cancer segment witnessed a significant revenue share in the proton therapy market in 2021. Since proton particles do not generate exit dosage, normal tissues located far from the tumor can be spared during proton therapy. Due to the anatomical restrictions present in almost all cancers in the head and neck region, this is very helpful for these tumors.
End User Outlook
By End-User, the Proton Therapy Market is divided into Hospitals, Proton Therapy Centers, and Others. The hospital segment procured the highest revenue share in the proton therapy market in 2021. Due to the rise in the prevalence of cancer, improvements in the hospital infrastructure, the use of high-tech equipment, and increased self-awareness about diseases, it is anticipated that this trend will continue during the projected period.
Regional Outlook
Region-wise, the Proton Therapy Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region acquired the largest revenue share in the proton therapy market in 2021. During the foreseeable term, dominance is anticipated to persist. This was ascribed to a strong healthcare system, a growth in elderly patients, favorable reimbursement regulations in the healthcare system, and an increase in the number of healthcare facilities that provide proton treatment..
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Toshiba Corporation, Siemens Healthineers AG (Siemens AG), Ion Beam Applications SA, Hitachi, Ltd., Mirion Technologies, Inc., Mevion Medical Systems, Inc., Provision Healthcare, Sumitomo Corporation and Optivus Proton Therapy, Inc.
Strategies Deployed in Proton Therapy Market
May-2022: Sun Nuclear Corporation, a subsidiary of Mirion Technologies unveiled SunSCAN 3D cylindrical water scanning system for beam scanning, linear accelerator commissioning, and annual Quality Assurance in Radiation Therapy. The new SunSCAN 3D water scanning system is an advanced addition to Sun Nuclear's complete solutions offering for independent, combined Quality Management of Diagnostic Imaging and Radiation Therapy.
May-2022: Ion Beam Applications took over Modus Medical Devices, a Canadian company based in London. With this acquisition, IBA would profit from synergies both in R&D and in sales and promote it to expand its product roster. Additionally, the acquisition would reinforce IBA's competitive standing globally along with its footprint in North America.
Mar-2022: Ion Beam Applications came into a partnership with Tractebel, a global engineering business. This partnership would sustain IBA's consumers with their proton therapy technique and construction schemes. Additionally, IBA would advertise Tractebel's consulting services to its future consumers connecting to the design and construction of their proton treatment facilities.
Nov-2021: Mirion Technologies completed the acquisition of CHP Dosimetry, a U.S.-based supplier of dosimetry services. The new CHP Dosimetry would continue to operate Mirion's strong dosimetry products.
Oct-2021: IBA introduced Campus, the world's first online platform committed to proton therapy. The new Campus allows consumers to share proton therapy-related materials and resources, along with conversation forums with other users, to assist researchers and clinicians in proton therapy to improve and discover new skills for the advantage of patients.
Oct-2021: IBA formed a partnership with RaySearch Laboratories, a world head in software for radiation therapy. Through this partnership, the companies aimed to expand their partnership in proton treatment within the regions of FLASH radiotherapy, proton ARC therapy, and therapy of moving tumors. Additionally, the RayCare oncology information system from RaySearch would be tailored for optimal benefit in conjunction with the IBA delivery solutions.
Sep-2021: Siemens Healthineers joined hands with The University of Texas MD Anderson Cancer Center. Through this collaboration, the companies aimed to develop a global education program focused on promoting the performance of consistent, high-quality magnetic resonance (MR) imaging in radiation oncology. Additionally, the program would deliver courses for both clinical and executive groups to promote secure adoption and wider clinical execution of MR to enhance outcomes for patients.
Apr-2021: Siemens Healthineers took over Varian Medical Systems, an American radiation oncology therapies, and software maker. With this acquisition, Siemens Healthineers has the most complete offering in the MedTech sector, which delivers the business's significant potential for value creation. Additionally, with a highly combined process, Siemens Healthineers would take the global battle against cancer to another level.
Sep-2020: Mevion Medical Systems signed an agreement with Proton International, a professional team committed to bringing Proton Therapy to organizations and patients. Through this agreement, the companies aimed to provide Mevion's close proton therapy solution to new centers in locations such as South Texas and the Southeast United States. Additionally, the new centers would offer the MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS). HYPERSCAN allows quicker and sharper delivery of therapeutic radiation to tumors.
Jan-2018: Hitachi Healthcare Americas took over VidiStar, a Greenville, S.C.-based business. Through this acquisition, VidiStar would advance the organization's informatics strategy and analytics abilities to enhance workflow and intelligence for physicians, specifically with those providers completing diagnostic ultrasound examinations.
Market Segments covered in the Report:
By Product Type
By Indication
By End User
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures